MIRA (MIRA Pharmaceuticals, Inc. Common Stock) Stock Analysis - News
MIRA Pharmaceuticals, Inc. Common Stock (MIRA) is a publicly traded Healthcare sector company. As of May 21, 2026, MIRA trades at $1.00 with a market cap of $41.01M and a P/E ratio of -0.72. MIRA moved +0.00% today. Year to date, MIRA is -35.06%; over the trailing twelve months it is -26.14%. Its 52-week range spans $0.73 to $2.56. Rallies surfaces MIRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in MIRA news today?
MIRA Pharmaceuticals Reports Safe Tolerability and Favorable PK in 57-Volunteer Ketamir-2 Phase 1 Trial: MIRA Pharmaceuticals reported positive data from its Phase 1 trial of Ketamir-2 in 57 volunteers, with no serious adverse events and lower adverse-event rate than placebo. Pharmacokinetics showed rapid oral absorption, dose-proportional Cmax and half-lives of 2.5–7 hours and 7–9 hours, supporting once-daily dosing and Phase 2a development in chemotherapy-induced peripheral neuropathy.
Aminov Erez sold 613.60K (~$1.29M) on Oct 16, 2025.
Aminov Erez sold 44.59K (~$56.63K) on Nov 20, 2024.
Aminov Erez sold 55.41K (~$77.02K) on Nov 19, 2024.
MIRA Analyst Consensus
MIRA analyst coverage data. Average price target: $0.00.
Common questions about MIRA
What changed in MIRA news today?
MIRA Pharmaceuticals Reports Safe Tolerability and Favorable PK in 57-Volunteer Ketamir-2 Phase 1 Trial: MIRA Pharmaceuticals reported positive data from its Phase 1 trial of Ketamir-2 in 57 volunteers, with no serious adverse events and lower adverse-event rate than placebo. Pharmacokinetics showed rapid oral absorption, dose-proportional Cmax and half-lives of 2.5–7 hours and 7–9 hours, supporting once-daily dosing and Phase 2a development in chemotherapy-induced peripheral neuropathy.
Does Rallies summarize MIRA news?
Yes. Rallies summarizes MIRA news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is MIRA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for MIRA. It does not provide personalized investment advice.
